^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
autologous CD7-CAR T cells
i
Other names: autologous CD7-CAR T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Beijing Boren Hospital
Drug class:
CD7-targeted CAR-T immunotherapy
Related drugs:
1year
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma (clinicaltrials.gov)
P1, N=16, Completed, Beijing Boren Hospital | Recruiting --> Completed
Trial completion
|
CD7 (CD7 Molecule)
|
cyclophosphamide • autologous CD7-CAR T cells
over3years
Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma (clinicaltrials.gov)
P1, N=20, Recruiting, Beijing Boren Hospital | Trial primary completion date: Apr 2022 --> Apr 2023
Trial primary completion date • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
cyclophosphamide • autologous CD7-CAR T cells
over3years
Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma. (ASCO 2022)
Autologous CD7 CAR T cell therapy was safe and effective in the induction of remission in r/r T-ALL/LBL patients, without signs of GVHD. Longer follow-up time of more cases will be used to further evaluate this therapy.
CAR T-Cell Therapy • IO biomarker
|
CD7 (CD7 Molecule)
|
CD7 expression
|
autologous CD7-CAR T cells
over4years
Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma (clinicaltrials.gov)
P1, N=20, Recruiting, Beijing Boren Hospital
Clinical • New P1 trial • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
autologous CD7-CAR T cells
Share via
